Loading clinical trials...

Impact of Tiotropium Add-on Therapy in Patients With Asthma | Clinical Trials | Clareo Health

COMPLETED

Impact of Tiotropium Add-on Therapy in Patients With Asthma

The Effectiveness of Tiotropium Add-on Therapy Using a Real-world Cohort of Patients With Asthma

NCT03964220•Boehringer Ingelheim

Summary

To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with least one asthma diagnosis in the inpatient setting or at least two separate instances of asthma diagnosis (separated by at least 30 days) recorded in the outpatient or emergency room setting will be included.
•Patients will be required to be already on Inhaled Corticosteroid/Long-acting beta-agonist (ICS/LABA).
•Patients will be required to have available records 12 months prior to the index date.

Exclusion Criteria

•Patients below the age of 6 years on the Inhaled Corticosteroid/Long-acting beta-agonist initiation (ICS/LABAi) date will be excluded.
•Patients with a diagnosis of COPD at any time during the study period will be excluded.
•Those who are on biologics at baseline will be removed.
•After the PSM process, unmatched patients will be excluded.

Locations (1)

eMax Health

White Plains, New York, United States

Key Dates

Start Date

March 15, 2019

Primary Completion Date

September 20, 2019

Completion Date

September 20, 2019

Last Updated

November 3, 2020

Enrollment

7,857

ACTUAL participants

Conditions

Asthma

Interventions

Tiotropium Respimat®

DRUG

Inhaled Corticosteroid/Long-acting beta-agonist

DRUG

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

RECRUITINGPHASE2

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173

Asthma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 3, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of Tiotropium Add-on Therapy in Patients With Asthma

Inclusion Criteria

Exclusion Criteria

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma